Peer-reviewed Publication Shows that Lateral Pharma's SCP Drugs for Neuropathic Pain Act Via the Novel Target LanCL1

Contributed by: PR Newswire

Tags

LATERAL-PHARMA-STUDY

More Like This

Progressive Supranuclear Palsy Phase 2 Platform Clinical Trial Announces the Selection of AADvac1 and AZP2006 for its First Two Regimens

Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain

Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy

Celosia Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of CTx1000 in Amyotrophic Lateral Sclerosis

Pain Cloud® Launch: A Collaboration between EptivA and Infopoly Ltd., creating an advanced solution to Pain Research

Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy

EQT Life Sciences invests in Asceneuron, a neurodegeneration therapeutics company, as part of USD 100 million Series C financing round

Oblique Therapeutics announces that NaV 1.8 project is advancing to next stage